Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Metformin attenuates lung fibrosis development via NOX4 suppression

Open access
Sato, Nahoko, Takasaka, Naoki, Yoshida, Masahiro, Tsubouchi, Kazuya, Minagawa, Shunsuke, Araya, Jun, Saito, Nayuta, Fujita, Yu, Kurita, Yusuke, Kobayashi, Kenji, Ito, Saburo, Hara, Hiromichi, Kadota, Tsukasa, Yanagisawa, Haruhiko, Hashimoto, Mitsuo, Utsumi, Hirofumi, Wakui, Hiroshi, Kojima, Jun, Numata, Takanori, Kaneko, Yumi, Odaka, Makoto, Morikawa, Toshiaki, Nakayama, Katsutoshi, Kohrogi, Hirotsugu, Kuwano, Kazuyoshi·2016·Respiratory Research

Abstract

BACKGROUND: Accumulation of profibrotic myofibroblasts in fibroblastic foci (FF) is a crucial process for development of fibrosis during idiopathic pulmonary fibrosis (IPF) pathogenesis, and transforming growth factor (TGF)-β plays a key regulatory role in myofibroblast differentiation. Reactive oxygen species (ROS) has been proposed to be involved in the mechanism for TGF-β-induced myofibroblast differentiation. Metformin is a biguanide antidiabetic medication and its pharmacological action is mediated through the activation of AMP-activated protein kinase (AMPK), which regulates not only energy homeostasis but also stress responses, including ROS. Therefore, we sought to investigate the inhibitory role of metformin in lung fibrosis development via modulating TGF-β signaling. METHODS: TGF-β-induced myofibroblast differentiation in lung fibroblasts (LF) was used for in vitro models. The anti-fibrotic role of metfromin was examined in a bleomycin (BLM)-induced lung fibrosis model. RESULTS: We found that TGF-β-induced myofibroblast differentiation was clearly inhibited by metformin treatment in LF. Metformin-mediated activation of AMPK was responsible for inhibiting TGF-β-induced NOX4 expression. NOX4 knockdown and N-acetylcysteine (NAC) treatment illustrated that NOX4-derived ROS generation was critical for TGF-β-induced SMAD phosphorylation and myofibroblast differentiation. BLM treatment induced development of lung fibrosis with concomitantly enhanced NOX4 expression and SMAD phosphorylation, which was efficiently inhibited by metformin. Increased NOX4 expression levels were also observed in FF of IPF lungs and LF isolated from IPF patients. CONCLUSIONS: These findings suggest that metformin can be a promising anti-fibrotic modality of treatment for IPF affected by TGF-β.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-016-0420-x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 228

Metadata

Authors
Sato, N., Takasaka, N., Yoshida, M., Tsubouchi, K., Minagawa, S., Araya, J., Saito, N., Fujita, Y., Kurita, Y., Kobayashi, K., Ito, S., Hara, H., Kadota, T., Yanagisawa, H., Hashimoto, M., Utsumi, H., Wakui, H., Kojima, J., Numata, T., Kaneko, Y., Odaka, M., Morikawa, T., Nakayama, K., Kohrogi, H., & Kuwano, K.
Venue
Respiratory Research
Published
2016-08-30
Volume
17
Issue
1
Pages
107-107
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W2516387951
Cited by
228
References
11
FWCI
17.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin attenuates lung fibrosis development via NOX4 suppression. https://app.cochat.ai/papers/10.1186/s12931-016-0420-x
The paper
Sato, N., Takasaka, N., Yoshida, M., Tsubouchi, K., Minagawa, S., Araya, J., Saito, N., Fujita, Y., Kurita, Y., Kobayashi, K., Ito, S., Hara, H., Kadota, T., Yanagisawa, H., Hashimoto, M., Utsumi, H., Wakui, H., Kojima, J., Numata, T., . . . Kuwano, K. (2016). Metformin attenuates lung fibrosis development via NOX4 suppression. Respiratory Research. https://doi.org/10.1186/s12931-016-0420-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.